REMARKS

In response to the Restriction Requirement mailed on May 31, 2006, Applicants elect Embodiment II for further prosecution. Applicants also elect SEQ ID NO:1 with traverse. Applicants submit herewith a Request for Extension of Time of two months thereby extending the period for response from July 1, 2006 to August 31, 2006. The undersigned hereby authorizes the charge of any fees created by the filing of this document or any deficiency of fees submitted herewith to be charged to deposit account No. 19-1970.

Claims 1-68 have been canceled and new claims 69-78 submitted.

Claims 69-71, 73 and 75-76 substantially track canceled claim 50.

Claim 72 is drawn to nucleic acid molecules encoding a protein 80% identical to specified SEQ ID NO's. Support for such nucleic acid molecules can be found in the specification, for example, on page 33, lines 3-6.

Claims 77 and 78 are drawn to fragments of nucleic acid molecules consisting of specific sequences. Support for such fragments can be found in the specification, for example, on page 39, lines 13-24, and on page 35, lines 29-31, through page 36, lines 1-6.

Accordingly, Applicants submit that no new matter has been entered in to the Application.

I. Group Election

Applicants have elected Embodiment II, drawn to isolated nucleic acid sequences and therapeutic compositions comprising such nucleic acid sequences, for further prosecution.

II. Sequence Election

Applicants have elected SEQ ID NO:1, with traverse, for further prosecution. SEQ ID NO:1 is a full length nucleic acid molecule the complement of which is SEQ ID NO:3. The protein encoded by SEQ ID NO:1 is represented by SEQ ID NO:2.

Applicants request the Examiner rejoin SEQ ID NO:1 with SEQ ID NO:28, it's corresponding complement SEQ ID NO:30, and with SEQ ID NO:50. As noted above, SEQ ID NO:1 is a full-length nucleic acid molecule encoding the V, D and J regions of a canine T-cell

receptor β chain. SEQ ID NO:28 is a truncated version of SEQ ID NO:1 and consequently is identical over its entire length to the corresponding region of SEQ ID NO:1. Furthermore, SEQ ID NO:50 is an oligonucleotide sequence identical in sequence to nucleotides 157-175 of SEQ ID NO:1 and SEQ IDNO:28. The relationship between these molecules is made clear by the following alignment:

```
SIN1            ATCGGACTCC TCTGTGGTGT GGCCTTTTGT TTCCTGGGAG TAGGCCTTTT
SIN28           ATCGGACTCC TCTGTGGTGT GGCCTTTTGT TTCCTGGGAG TAGGCCTTTT


SIN1            GAACGCACAA GTGACTCAAA CCCCGAGACA ACTCATCAAA AAAGTGGGAG
SIN28           GAACGCACAA GTGACTCAAA CCCCGAGACA ACTCATCAAA AAAGTGGGAG


SIN1            CGAAAGTTTT GTTGAAATGT TCACAGAATA TGGACCATGA AAGAATGTTC
SIN28           CGAAAGTTTT GTTGAAATGT TCACAGAATA TGGACCATGA AAGAATGTTC


SIN1            TGGTATCGAC AAGACCCAGG TCTGGGGTTG CGGCTGCTCT ACTGGTCCTA
SIN28           TGGTATCGAC AAGACCCAGG TCTGGGGTTG CGGCTGCTCT ACTGGTCCTA
SIN50                 CGAC AAGACCCAGG TCTGG

SIN1            TAATATTGAC AGTGTTGAGA CAGGAGACAT CCCTTATGGG TACAGTGTCT
SIN28           TAATATTGAC AGTGTTGAGA CAGGAGACAT CCCTTATGGG TACAGTGTCT


SIN1            CGAGGAAGAA GAAGGATGCC TTCCCCTTGA TTCTGGAGTC TGCTCGCATC
SIN28           CGAGGAAGAA GAAGGATGCC TTCCCCTTGA TTCTGGAGTC TGCTCGCATC


SIN1            AACCAGACAT CTGTGTACTT CTGCGCCAGC AGCccgttta gccaaaatac
SIN28           AACCAGACAT CTGTGTACTT CTGCGCCAGC AGC..... .........


SIN1            ccagtacttc ggggcgggca cccggctgct a
SIN28           ......... ......... ......... .
```

It is clear from the above that SEQ ID NO:1, SEQ ID NO:28 and SEQ ID NO:50 are identical over their entire lengths to the corresponding region of SEQ ID NO:1. Consequently, SEQ ID NO:3 and SEQ ID NO:30, which are the complements of SEQ ID NO's 1 and 28, respectively, are also identical in their overlapping regions. Thus, Applicants request that SEQ ID NO's 1, 3, 28 and 30, and the proteins encoded by these sequences (i.e., SEQ ID NO:2 and SEQ ID NO:29) be rejoined and examined together since Applicants contend such a search would not pose an undue burden on the Examiner.

Applicants further request SEQ ID NO's 60-61 be rejoined and Examined with SEQ ID NO's 1 ,2, 3, 28, 29, 30 and 50. As noted above, SEQ ID NO's 2 and 29 represent the amino acid sequence of the V, D and J regions of a canine T-cell receptor. As noted in the specification, for example, on page 18, lines 4-19, it is known in the art that the sequence between the V and D regions can vary. Thus SEQ ID NO's 60-62, which represent sequence from the carboxyl end of the V region, are substantially identical to SEQ ID NO's 2 and 29 as shown in the following alignment:

```
SIN2            IGLLCGVAFC FLGVGLLNAQ VTQTPRQLIK KVGAKVLLKC SQNMDHERMF
SIN29           IGLLCGVAFC FLGVGLLNAQ VTQTPRQLIK KVGAKVLLKC SQNMDHERMF
SIN60           IGLLCGVAFC FLGVGLLNAQ VTQTPRQLIK KVGRKVLLKC SQNMDHER..
SIN61           IGLLCGVAFC FLGVGLLNAQ VTQTPRQLIK KVGRKVLLKC SQNMDHER..
SIN62           IGLLCGVAFC FLGVGLLNAQ VTQTPRQLIK KVGRKVLLKC SQNMDHER..


SIN2            WYRQDPGLGL RLLYWSYNID SVETGDIPYG .......... ......YSVS
SIN29           WYRQDPGLGL RLLYWSYNID SVETGDIPYG .......... ......YSVS
SIN60           .......... ....WSYNID SVETGDIPYG MFWYQQDPGL GLRLLYYSVS
SIN61           .......... ....WSYNID SVETGDIPYG MFWYQQDPGL GLRLLYYSVS
SIN62           .......... ....WSYNID SVETGDIPYG MFWYQQDPGL GLRLLYYSVS


SIN2            RKKKDAFPLI LESARINQTS VYFCASSpfs qntqyfgagt rll
SIN29           RKKKDAFPLI LESARINQTS VYFCASS... .......... ...
SIN60           RKKKDAFPLI LESARINQTS VYFCx..... .......... ...
SIN61           RKKKDAFPLI LESARINQTS VYFCxx.... .......... ...
SIN62           RKKKDAFPLI LESARINQTS VYFCxxx... .......... ...
```

The above makes it clear that SEQ ID NO's 60-62 are substantially identical to SEQ ID NO's 2 and 29. Applicants therefore request the Examiner rejoin SEQ ID NO's 60-62, and in particular nucleic acid sequences encoding these sequences, with SEQ ID NO's 1-3, 28-30 and 50 since Applicants contend a search for all of these molecules would be co-extensive and would not pose an undue burden on the Examiner.

CONCLUSION

Applicants believe all of the claims to be in condition for allowance. If it would be helpful to obtain favorable consideration of this case, the Examiner is encouraged to call and discuss this case with the undersigned.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: /Darla G. Yoerg/
Darla G. Yoerg
Registration No. 48,053
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
(303) 863-9700

Date: August 30, 2006